| Bacterial load (16S rRNA copies) | Shannon diversity index | |||||
---|---|---|---|---|---|---|---|
*Variable | Levels | aNumber of observations (n = 875) | Participants (n = 346) | 1Adjusted co-efficient (95% CI) | 1p value | 2Adjusted co-efficient (95% CI) | 2p value |
Visit | Placebo at week 48 | 150 (17.1%) | 150 (43.4%) | Reference | Â | Reference | Â |
AZM at week 48 | 154 (17.6%) | 154 (44.5%) | − 0.46 [− 0.63; − 0.29] | < 0.0001 | 0.25 [0.07; 0.42] | 0.01 | |
Placebo at week 72 | 117 (13.4%) | 117 (33.8%) | Reference | Â | Reference | Â | |
AZM at week 72 | 123 (14.1%) | 123 (35.5%) | − 0.19 [− 0.38; 0.0] | 0.051 | 0.2 [0.01; 0.40] | 0.04 | |
Site | Malawi | 233 (26.6%) | 106 (30.6%) | Reference | Â | Reference | Â |
Zimbabwe | 642 (73.4%) | 240 (69.4%) | 0.3 [0.11; 0.49] | 0.003 | 0.27 [0.06; 0.47] | 0.01 | |
Medical Research Council dyspnoea score at baseline | 1 | 479 (54.7%) | 184 (53.2%) | Â | Â | Reference | Â |
2 | 316 (36.1%) | 126 (36.4%) | Â | Â | 0.26 [0.1; 0.42] | 0.04 | |
3 | 53 (6.1%) | 23 (6.6%) |  |  | 0.16 [− 0.18; 0.49] |  | |
4 | 23 (2.6%) | 11 (3.2%) |  |  | 0.25 [− 0.21; 0.71] |  | |
5 | 4 (0.5%) | 2 (0.6%) |  |  | 0.52 [− 1.05; 2.09] |  | |
Forced expiratory volume in 1 s (FEV1) z-score (FEV1z) |  | 862 (98.5%) | 346 (100%) | − 0.09 [− 0.16; − 0.02] | 0.02 | 0.19 [0.12; 0.27] | < 0.001 |
Ever treated for tuberculosis before enrolment | No | 609 (69.8%) | 248 (71.9%) | Reference | Â | Reference | Â |
Yes | 263 (30.2%) | 97 (28.1%) | 0.17 [0.03; 0.32] | 0.02 | − 0.19 [− 0.34; − 0.04] | 0.02 |